Immune Checkpoint Inhibitors in Hematologic Malignancies (HM)

Immune Checkpoint Inhibitors in Hematologic Malignancies (HM)

Dr. Hongtao Liu, assistant professor of medicine, examines CTLA-4 inhibition in hematologic malignancies and discusses the ongoing checkpoint inhibitor trials.


Published

May 20, 2016

Created by

The University of Chicago Medicine

Related Presenters

Liu

Hongtao Liu, MD, PhD

Assistant Professor of Medicine

Hongtao Liu, MD, PhD, is a medical oncologist, specializing in the diagnosis and treatment of leukemia. He provides the highest level of care for patients undergoing stem cell transplantation and other aggressive therapies, including chemotherapy. In ...